Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours

BACKGROUND: BAL101553 (lisavanbulin), the lysine prodrug of BAL27862 (avanbulin), exhibits broad anti-proliferative activity in human cancer models refractory to clinically relevant microtubule-targeting agents. METHODS: This two-part, open-label, phase 1/2a study aimed to determine the maximum tole...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristeleit, Rebecca, Evans, Jeffry, Molife, L. Rhoda, Tunariu, Nina, Shaw, Heather, Slater, Sarah, Haris, Noor R. Md, Brown, Nicholas F., Forster, Martin D., Diamantis, Nikolaos, Rulach, Robert, Greystoke, Alastair, Asghar, Uzma, Rata, Mihaela, Anderson, Stephanie, Bachmann, Felix, Hannah, Alison, Kaindl, Thomas, Lane, Heidi A., Larger, Patrice J., Schmitt-Hoffmann, Anne, Engelhardt, Marc, Tzankov, Alexandar, Plummer, Ruth, Lopez, Juanita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591872/
https://www.ncbi.nlm.nih.gov/pubmed/32741975
http://dx.doi.org/10.1038/s41416-020-1010-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591872/
https://www.ncbi.nlm.nih.gov/pubmed/32741975
http://dx.doi.org/10.1038/s41416-020-1010-8

Ejemplares similares